World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
86
Citations
38716
World Ranking
13895
National Ranking
7055

Overview

Aditya Bardia is affiliated with Harvard University in the United States. Their research contributions primarily focus on oncology and related biomedical fields, with a significant body of work in advanced breast cancer therapies.

Their publication record includes papers in notable journals such as The Lancet, New England Journal of Medicine, Clinical Cancer Research, and the Journal of Clinical Oncology. Some recent papers include:

  • "Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study," 2020, The Lancet
  • "Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer," 2021, New England Journal of Medicine
  • "Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis," 2020, Clinical Cancer Research
  • "Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial," 2022, Journal of Clinical Oncology
  • "Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future," 2020, The Lancet

Frequent coauthors in Bardia's research include:

  • Laura M. Spring
  • Hope S. Rugo
  • Leif W. Ellisen
  • Seth A. Wander
  • Beverly Moy

Their research has appeared consistently in several prominent publication venues, among which are:

  • Cancer Research
  • Journal of Clinical Oncology
  • Clinical Cancer Research
  • Annals of Oncology
  • npj Breast Cancer

Bardia's main fields of study encompass Medicine and Biochemistry, Genetics and Molecular Biology. Within these broader fields, subfields of focus include:

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research
  • Genetics
  • Radiology, Nuclear Medicine and Imaging

The major topics covered in their work highlight:

  • Advanced Breast Cancer Therapies
  • HER2/EGFR in Cancer Research
  • Cancer Treatment and Pharmacology
  • Cancer Genomics and Diagnostics
  • Breast Cancer Treatment Studies
  • Estrogen and related hormone effects
  • Cancer-related Molecular Pathways

Best Publications

  • Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition

    Min Yu;Aditya Bardia;Ben S. Wittner;Shannon L. Stott

  • Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis

    Nicola Aceto;Aditya Bardia;David T. Miyamoto;Maria C. Donaldson

  • Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.

    Nicole M. Kuderer;Toni K. Choueiri;Dimpy P. Shah;Yu Shyr

  • Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

    Aditya Bardia;Sara A Hurvitz;Sara M Tolaney;Delphine Loirat

  • Inertial Focusing for Tumor Antigen–Dependent and –Independent Sorting of Rare Circulating Tumor Cells

    Emre Ozkumur;Ajay M. Shah;Jordan C. Ciciliano;Benjamin L. Emmink

  • Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility

    Min Yu;Min Yu;Aditya Bardia;Nicola Aceto;Francesca Bersani

  • Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial

    Debu Tripathy;Seock Ah Im;Marco Colleoni;Fabio Franke

  • Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer

    Seock-Ah Im;Yen-Shen Lu;Aditya Bardia;Nadia Harbeck

  • Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.

    Aditya Bardia;Ingrid A Mayer;Linda T Vahdat;Sara M Tolaney

  • A microfluidic device for label-free, physical capture of circulating tumor cell clusters

    A Fatih Sarioglu;Nicola Aceto;Nikola Kojic;Maria C Donaldson

  • Malignant Melanoma in the 21st Century, Part 1: Epidemiology, Risk Factors, Screening, Prevention, and Diagnosis

    Svetomir N. Markovic;Lori A. Erickson;Ravi D. Rao;Robert R. McWilliams

  • Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis.

    Laura M. Spring;Geoffrey Fell;Andrea Arfe;Chandni Sharma

  • Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

    Aditya Bardia;Ingrid A. Mayer;Jennifer R. Diamond;Rebecca L. Moroose

  • Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models

    Ioanna Keklikoglou;Chiara Cianciaruso;Esra Güç;Mario Leonardo Squadrito

  • Hand-Foot Syndrome After Dose-Dense Adjuvant Chemotherapy for Breast Cancer: A Case Series

    Aditya Bardia;Charles L. Loprinzi;Matthew P. Goetz

  • HER2 expression identifies dynamic functional states within circulating breast cancer cells

    Nicole Vincent Jordan;Aditya Bardia;Ben S. Wittner;Cyril Benes

  • Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer

    R. Condorelli;L. Spring;J. O’Shaughnessy;L. Lacroix

  • Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future.

    Laura M Spring;Seth A Wander;Fabrice Andre;Beverly Moy

  • Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis

    Laura M. Spring;Arjun Gupta;Kerry L. Reynolds;Michele A. Gadd

  • Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer

    Luigi Formisano;Yao Lu;Alberto Servetto;Ariella B. Hanker;Ariella B. Hanker

Frequent Co-Authors

Sara A. Hurvitz
Sara A. Hurvitz Fred Hutchinson Cancer Research Center
Daniel A. Haber
Daniel A. Haber Harvard University
Hope S. Rugo
Hope S. Rugo University of California, San Francisco
David M. Goldenberg
David M. Goldenberg Immunomedics (United States)
Sara M. Tolaney
Sara M. Tolaney Harvard University
Joyce O'Shaughnessy
Joyce O'Shaughnessy Baylor University Medical Center
Ingrid A. Mayer
Ingrid A. Mayer Vanderbilt University Medical Center
Nadia Harbeck
Nadia Harbeck Ludwig-Maximilians-Universität München
Robert M. Sharkey
Robert M. Sharkey University of Fukui
Mehmet Toner
Mehmet Toner Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in Medicine doesn’t always require a lengthy on-campus degree. There are flexible online pathways for those seeking advanced credentials in nursing and related healthcare fields. For nurses aiming for leadership roles quickly, a 1 year dnp program online offers an accelerated route to earning a Doctor of Nursing Practice from home.

If you’re interested in a streamlined academic experience, some online dnp programs without dissertation eliminate traditional research requirements, making it easier for working professionals to advance their qualifications while managing their schedules.

For those just starting out in nursing, short-term licensure programs are available. You can complete a 6 month lpn program online to enter the career field swiftly. These programs are designed to quickly equip students with essential clinical skills.

Specializing in mental health is also possible with a shorter timeline through the shortest pmhnp program options, allowing qualified nurses to become Psychiatric Mental Health Nurse Practitioners in record time.

These flexible online degree pathways can help you find the right fit for your goals while minimizing time away from work and family.

Best Scientists Citing Aditya Bardia

Trending Scientists

Recently Published Articles